Evidence map›Paper›PMID 25133421›Full record

ArticleThe Journal of clinical investigation2014

Healing the injured vessel wall using microRNA-facilitated gene delivery.

Mark W Feinberg

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Platelet microRNAs and vascular injury.The Journal of clinical investigation · 2019
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mark W Feinberg
Brigham and Women's Hospital · US

Funding

MiR-181b, endothelial cells, and vascular inflammationR01HL115141 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2012 to 2024
$6.8M
MiR-26a, endothelial cells, and neovascularizationR01HL117994 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2013 to 2016
$1.6M
NHLBI NIH HHS HL115141NHLBI NIH HHS HL117994NHLBI NIH HHS R01 HL115141NHLBI NIH HHS R01 HL117994
6 · The paper itself

Abstract

Drug-eluting stents have emerged as potent weapons in the treatment of patients with symptomatic coronary artery disease by reducing restenosis rates; however, a significant clinical consequence of these stents is delayed reendothelialization, which may increase the risk of late stent thrombosis. In this issue of the JCI, Santulli and colleagues generated an adenovirus that expresses the cyclin-dependent kinase inhibitor p27(Kip1) (p27) and bears four tandem copies of target sequences for the endothelial cell-enriched microRNA (miRNA) miR-126-3p (Ad-p27-126TS) in an attempt to specifically reduce proliferation of vascular smooth muscle cells, but not endothelial cells. Indeed, delivery of Ad-p27-126TS to balloon-injured arteries in rats not only induced faster and more complete reendothelialization, but also effectively improved neointimal hyperplasia, hypercoagulability, and vasoreactivity. Collectively, these findings provide a cogent foundation for the potential therapeutic use of miRNA-facilitated gene delivery strategies to heal vessel wall injury.

Indexed as

AnimalsCoronary RestenosisCyclin-Dependent Kinase Inhibitor p27Endothelial CellsHumansMaleMicroRNAsCyclin-Dependent Kinase Inhibitor p27MicroRNAsMIRN126 microRNA, human

Identifiers

PMID25133421
PMCPMC4151224
OpenAlexW1985342345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.